Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression

Summary: Therapeutic neoantigen cancer vaccines have limited clinical efficacy to date. Here, we identify a heterologous prime-boost vaccination strategy using a self-assembling peptide nanoparticle TLR-7/8 agonist (SNP) vaccine prime and a chimp adenovirus (ChAdOx1) vaccine boost that elicits poten...

Full description

Bibliographic Details
Main Authors: Ramiro A. Ramirez-Valdez, Faezzah Baharom, Ahad Khalilnezhad, Sloane C. Fussell, Dalton J. Hermans, Alexander M. Schrager, Kennedy K.S. Tobin, Geoffrey M. Lynn, Shabnam Khalilnezhad, Florent Ginhoux, Benoit J. Van den Eynde, Carol Sze Ki Leung, Andrew S. Ishizuka, Robert A. Seder
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Cell Reports
Subjects:
CP: Cancer
CP: Immunology
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124723006101

Internet

http://www.sciencedirect.com/science/article/pii/S2211124723006101

Similar Items